The Inhibrx Mission

Our mission is to discover and develop effective biologic therapeutics for people with life-threatening conditions.

Toward this goal, we’ve developed a diverse pipeline of therapeutic candidates specifically designed to leverage the power of our core sdAb (single-domain antibody) platform and protein-engineering expertise.

Our Scientific Approach

Learn more

Because of their stable nature and simple structure, our sdAbs are the ideal building blocks for constructing novel biologics.

Chart

Our History

Over the last 15 years, we’ve successfully leveraged our proprietary technology and protein engineering expertise to develop a portfolio of highly differentiated clinical development programs.

Inhibrx, Inc. was founded in 2010, and we had our first application for an investigational new drug approved in 2018. In 2020, Inhibrx, Inc. became a publicly traded company. In May 2024, the INBRX-101 program was sold to Sanofi. Inhibrx Biosciences, Inc., a spin-off of Inhibrx, Inc. was formed immediately prior to the sale to take possession of the non-INBRX-101 assets and continues to advance ozekibart (INBRX-109) and INBRX-106, our therapeutic candidates which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function.

Meet our team
Inhibrx Culture

Our Culture

At Inhibrx you’ll not only find a cohort of established, focused, and meticulous scientists, but also a close-knit, creative, and adventurous team. With a shared vision and intrinsic motivation to get there, we inspire each other to go further, look at opportunities from all angles, and push the boundaries of what’s possible in our daily work.

Echoing our versatile technology, we pride ourselves on providing flexibility and autonomy at our headquarters in San Diego, California. Instead of siloing our departments, we emphasize collaboration and a cross-disciplinary approach. We foster the pioneering spirit that makes us who we are—and also empower our people to do what they do best.